3. Function of the Core Unit as a Resource to the PEG The function of the Hematology and Clinical Chemistry Core (Core E) is to perform specific assays to accurately identify phenotypic abnormalities in the hematopoietic and metabolic functions of the genetically altered mouse strains to be studied in this PEG. Results from this Core will be recorded, analyzed, interpreted, and delivered to the Project Leaders in forms that are readily accessed and compared, such as Excel spreadsheets and common graphic files. The phenotypic data will help identify specific cell types affected and guide future experiments. In addition, where appropriate. Core E will assist in the training of each project's members, including postdoctoral fellows, in the techniques of hematology and clinical chemistry. The following screening assays will be performed on each genetically altered strain: 1. Hematology screen: Complete blood count with white cell subsets (differential count) and microscopic examination of peripheral blood smears for cellular morphology 2. Cytokine screen: a panel of acute phase and inflammatory cytokines will be measured which includes ILIA, IL1B, IL2, IL4, ILO, ILIO, ILI2, IL17A, IFNy, TNFa, G-CSF, and GM-CSF. 3. Metabolic screen: serum electrolytes, total protein, IgG immunoglobulin, liver enzymes (AST, ALT, ALP), and lipids (LDL, HDL, TG) to evaluate the overall functions of the liver, pancreas, and kidney, as well as the general metabolic status of the animal. 4. Hemostasis screen: prothrombin time (PT) and activated partial thromboblastin time (aPTT). 5. Urinary screen: pH, specific gravity, protein content, glucose, ketones, and nitrite Depending on the results of these screening tests, additional specific assays will be performed in consultation with the project leaders. In addition, depending on the specific aims of individual project, other directed functions will be performed by the Core. These functions are described under each project's Specific Aims.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL107150-03
Application #
8477272
Study Section
Special Emphasis Panel (ZHL1-CSR-H)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
3
Fiscal Year
2013
Total Cost
$149,699
Indirect Cost
$53,118
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Patras, Kathryn A; Nizet, Victor (2018) Group B Streptococcal Maternal Colonization and Neonatal Disease: Molecular Mechanisms and Preventative Approaches. Front Pediatr 6:27
Raitman, Irene; Huang, Mia L; Williams, Selwyn A et al. (2018) Heparin-fibronectin interactions in the development of extracellular matrix insolubility. Matrix Biol 67:107-122
Dokoshi, Tatsuya; Zhang, Ling-Juan; Nakatsuji, Teruaki et al. (2018) Hyaluronidase inhibits reactive adipogenesis and inflammation of colon and skin. JCI Insight 3:
Miles, L A; Baik, N; Bai, H et al. (2018) The plasminogen receptor, Plg-RKT, is essential for mammary lobuloalveolar development and lactation. J Thromb Haemost 16:919-932
Qiu, Hong; Shi, Songshan; Yue, Jingwen et al. (2018) A mutant-cell library for systematic analysis of heparan sulfate structure-function relationships. Nat Methods 15:889-899
Godula, Kamil (2018) Following sugar patterns in search of galectin function. Proc Natl Acad Sci U S A 115:2548-2550
Huang, Mia L; Michalak, Austen L; Fisher, Christopher J et al. (2018) Small Molecule Antagonist of Cell Surface Glycosaminoglycans Restricts Mouse Embryonic Stem Cells in a Pluripotent State. Stem Cells 36:45-54
Huang, Mia L; Tota, Ember M; Verespy 3rd, Stephen et al. (2018) Glycocalyx Scaffolding to Control Cell Surface Glycan Displays. Curr Protoc Chem Biol 10:e40
Ge, Xiao Na; Bastan, Idil; Ha, Sung Gil et al. (2018) Regulation of eosinophil recruitment and allergic airway inflammation by heparan sulfate proteoglycan (HSPG) modifying enzymes. Exp Lung Res 44:98-112
Gordts, Philip L S M; Esko, Jeffrey D (2018) The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis. Matrix Biol 71-72:262-282

Showing the most recent 10 out of 110 publications